-+ 0.00%
-+ 0.00%
-+ 0.00%

LYELL IMMUNOPHARMA, - ADDITIONAL CLINICAL DATA AND END-OF-PHASE 1 FDA MEETING EXPECTED IN 2027

Reuters·09/10/2026 20:05:01

Please log in to view news